December 14, 2018
Oct. 27, 2018--MGI, a subsidiary of BGI Group, introduced its newest model of genetic sequencer, MGISEQ-T7, which vastly improves speed, throughput and flexibility, at the 13th International Conference on Genomics (ICG-13) in Shenzhen. The most powerful MGI sequencer to date, MGISEQ-T7 is built with innovative quadruple flow-cell staging that allows simultaneous but independent operation of 1 to 4 flow cells in a single run. The MGI proprietary technology used in T7 delivers higher accuracy and improves efficiency through upgrades to the flow cell, fluid, and biochemical and optical system. A supercomputer for the life science industry, MGISEQ-T7 takes the production capacity of the sequencer to a new level with daily output of data up to 6Tb.
The MGISEQ-T7's innovations include:
Unique Quad-Flowcell Platform, supporting independent operation of 1-4 chips
A revolutionary quad-flow cell platform enables multiple flow cells with different read lengths and applications to be processed independently at any time in a single run. The platform supports whole genome sequencing, ultra-depth exome sequencing, epigenome sequencing, and large-panel tumor gene detection.
Sequencing speed increased by over 50%
MGISEQ-T7 runs much faster than any other sequencer to date. PE150 takes less than 24 hours at full load to complete.
Single chip density increased by 20%
MGISEQ-T7's chip density is increased by 20%. Terabyte-level data can be produced with a single chip.
The ultra-fast, ultra-high-throughput MGISEQ-T7 can complete WGS for up to 60 human genomes in a single day, breaking barriers for what a next generation sequencer can do. MGISEQ-T7 accelerates the development of nationwide genomics projects, since a T7 can complete the sequencing of 10,000 genomes within a year.